Literature DB >> 31190333

Downregulation of miR-218 by nicotine promotes cell proliferation through targeting CDK6 in non-small cell lung cancer.

Zhen Liu1, Cuiling Lu1, Guanren Zhao1, Xue Han1, Kaisheng Dong1, Chuanhai Wang2, Jing-Zhi Guan1, Zhongyuan Wang1.   

Abstract

BACKGROUND: Nicotine, an important component of tobacco, is a major risk factor of lung cancer, but the mechanism through which nicotine promotes lung cancer development remains unclear.
METHODS: Eighty patients with lung cancer were enrolled in this study, 34 of whom did not smoke and the others did. The expression of miR-218 and CDK6 messenger RNA (mRNA) was measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). A luciferase reporter system was used to identify the direct target of miR-218. The protein expression of CDK6 was analyzed by using Western blotting. Cell proliferation was analyzed using an approach of calculation of cell number under a microscope.
RESULTS: Nicotine decreased miR-218 expression in non-small cell lung cancer (NSCLC) cells and promoted proliferation of NSCLC cells. Smoking patients with NSCLC had lower expression of miR-218 in tumor compared with NSCLC patients who did not smoke. We found that miR-218 directly targeted the CDK6 mRNA 3'untranslated region and inhibited its expression in NSCLC cells and also observed a negative correlation between the expression of miR-218 and CDK6 mRNA in lung cancer tissues. Furthermore, miR-218- or nicotine-induced proliferative effects of NSCLC cells were rescued by the recovery of the expression level of CDK6.
CONCLUSION: Nicotine promotes proliferation of NSCLC cells through regulating the miR-218/CDK6 axis, which may be a potential therapeutic target for lung cancer.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CDK6; cell proliferation; miR-218; nicotine; non-small cell lung cancer

Mesh:

Substances:

Year:  2019        PMID: 31190333     DOI: 10.1002/jcb.29148

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

1.  Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.

Authors:  Rui Mu; Hongliang Liu; Sheng Luo; Edward F Patz; Carolyn Glass; Li Su; Mulong Du; David C Christiani; Lei Jin; Qingyi Wei
Journal:  Int J Cancer       Date:  2021-06-10       Impact factor: 7.396

2.  Effects and mechanism of microRNA‑218 against lung cancer.

Authors:  Yan Chen; Ji-Lin Yang; Zhen-Zhen Xue; Qiu-Chen Cai; Chun Hou; Hong-Juan Li; Liu-Xin Zhao; Yin Zhang; Cheng-Wei Gao; Li Cong; Tian-Zuo Wang; Dong-Mei Chen; Guo-Sheng Li; Shi-Qing Luo; Qian Yao; Chan-Juan Yang; Qi-Shun Zhu; Chuan-Hai Cao
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

3.  LncRNA PCGEM1 contributes to malignant behaviors of glioma by regulating miR-539-5p/CDK6 axis.

Authors:  Shu-Li Liu; Mao-Hua Chen; Xiao-Bo Wang; Rong-Kai You; Xue-Wei An; Qiu Zhao; Ren-Shu Wang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

4.  Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer.

Authors:  Wangang Gong; Lifang Wang; Zhiguo Zheng; Wenhu Chen; Peng Du; Hongguang Zhao
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

5.  Role of miR-218-GREM1 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma: An in vivo and vitro study based on microarray data.

Authors:  Yanpeng Wang; Yifeng Jiang; Long Chen
Journal:  J Cell Mol Med       Date:  2020-10-27       Impact factor: 5.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.